GlaxoSmithKline Pharmaceuticals Limited shareholders have overwhelmingly approved the appointment of Ronojit Biswas as Director and Whole-time Director & Chief Financial Officer, with both ordinary resolutions receiving near-unanimous support through postal ballot e-voting. 

According to the company’s filing with the stock exchanges, the first resolution for Biswas’ appointment as Directorwas passed with 99.69% of valid votes in favour, while only 0.31% voted against. A total of 14.19 crore shares backed the resolution, reflecting strong institutional and public shareholder support. 

The second and more strategic resolution approving his appointment as Whole-time Director and CFO secured an even stronger 99.76% approval, with 14.20 crore shares voting in favour and just 0.24% opposing the move. 

The remote e-voting process, conducted between March 9 and April 8, saw an overall voter participation of 84.04% of outstanding shares, a robust turnout for a postal ballot exercise and a signal of strong shareholder engagement on key management appointments. 

With the postal ballot now concluded, the appointments take effect from April 8, 2026, marking a clear shareholder endorsement of the company’s leadership roadmap and financial stewardship.